Mission Statement, Vision, & Core Values (2026) of RUNBEN BIOTECHNOLOGY.

Founded in 1993 and listed on the Shanghai Stock Exchange as 603193.SS, Runben Biotechnology-headquartered in Guangzhou and a subsidiary of Guangzhou Zhuofan Investment Holding Co., Ltd.-has rapidly scaled from mosquito repellents and baby care essentials into a biotech contender with a market capitalization of 9.81 billion yuan (as of December 12, 2025) and reported revenue of 1.32 billion yuan in 2024, a striking 27.61% year‑over‑year increase driven by expansion of its product portfolio and R&D‑led innovations; guided by a mission that channels approximately 20% of revenue into research and collaboration with healthcare professionals, Runben committed to a $150 million R&D investment in 2024 while pursuing a vision to enter 10 new countries, run five major clinical trials involving over 2,000 patients, and cut carbon emissions by 30% over five years-anchored by core values of innovation, integrity, collaboration, quality, and accountability that power both its consumer brands and clinical ambitions.

RUNBEN BIOTECHNOLOGY (603193.SS) - Intro

• Core business lines: mosquito repellent products, baby care products, essential oils.
• Geographic focus: domestic China with expanding retail & e-commerce distribution channels.
• Public listing: Shanghai Stock Exchange - ticker 603193.

• Deliver safe, science-backed personal care and household protection solutions that reduce vector-borne disease risk and improve daily wellbeing.
• Maintain product safety and regulatory compliance across all manufacturing lines, achieving consistent quality control benchmarks in GMP-certified facilities.

• Be a leading household and consumer-health brand in China and selected international markets, leveraging R&D to expand functional essential oil and infant-care portfolios.
• Scale revenue sustainably: target mid-to-high single-digit CAGR beyond 2025 while maintaining gross margin expansion through product mix optimization and cost efficiencies.

• Science-led innovation - commitment to R&D investment in active repellents and gentle formulations for infants.
• Consumer safety - strict adherence to product testing, traceability, and post-market surveillance.
• Sustainability - responsible sourcing of botanical inputs and reduction of volatile organic emissions.
• Integrity & compliance - transparent governance as a publicly listed company and alignment with shareholder interests.

RUNBEN BIOTECHNOLOGY (603193.SS) - Overview

• R&D intensity: ~20% of revenue allocated to research and development, with emphasis on advanced biopharmaceuticals and biologics.
• Collaboration: Active partnerships with hospitals, academic institutions, and contract research organizations to accelerate clinical translation.
• Access and impact: Programs targeting underserved domestic and international markets to address key public-health gaps.
• Sustainability: Product development and manufacturing optimized for lower waste, reduced carbon intensity, and resource efficiency.

• Target areas: monoclonal antibodies, recombinant proteins, biosimilars, and diagnostic biologics.
• Investment focus: early-stage discovery platforms, process intensification, and translational clinical programs.
• Outcomes-driven: pipeline prioritization tied to clinical milestones and commercial potential in underserved indications.

• Clinical partnerships with tertiary hospitals to run investigator-initiated and company-sponsored trials.
• Licensing and co-development agreements to de-risk late-stage assets and accelerate market entry.
• Shared data initiatives and academic collaborations to drive evidence generation and regulatory alignment.

• Pricing and distribution models designed to improve affordability in lower-income regions.
• Capacity investments to ensure supply reliability for public-health programs and institutional buyers.
• Localized registration strategies to shorten time-to-market in priority emerging markets.

• Green manufacturing: process optimizations to reduce solvent use, water consumption, and waste streams.
• Energy strategy: retrofitting facilities for improved energy efficiency and partial transition to renewable electricity.
• Supply-chain stewardship: supplier audits, sustainable sourcing, and packaging reduction initiatives.

• Board oversight of R&D portfolio and sustainability performance with defined reporting cadence.
• Cross-functional committees (R&D, commercial, compliance, sustainability) to align operational execution with mission goals.
• Stakeholder engagement program including healthcare providers, patient groups, regulators, and investors.

RUNBEN BIOTECHNOLOGY (603193.SS) Mission Statement

• Investing in breakthrough science: targeted biologics, cell and gene therapies, and precision diagnostics.
• Patient-centric development: inclusive clinical programs and post-market support to optimize real-world outcomes.
• Global reach with local impact: expanding access while ensuring regulatory compliance and ethical standards.
• Sustainable operations: reducing environmental footprint across R&D and manufacturing.

• Innovation pipeline acceleration: allocate increased R&D budget to shorten time-to-clinic and diversify modality portfolio.
• Clinical rigor and diversity: run five major trials in 2024 across multiple regions and demographics to ensure broad efficacy and safety data.
• International expansion: regulatory, commercial, and distribution initiatives to establish presence in 10 new countries by year-end.
• Sustainability integration: embed a 30% emissions reduction target into capital planning, supplier selection, and facility operations.

RUNBEN BIOTECHNOLOGY (603193.SS) - Vision Statement

• Global leadership in niche biologics and regenerative medicine within 7-10 years, targeting double-digit CAGR in specialty product revenue.
• Pipeline advancement: progression of multiple first-in-class and best-in-class candidates through Phase I-III clinical stages annually.
• Operational excellence: achieving and sustaining international GMP and ISO certifications across major facilities.

• Innovation - Continuous investment in R&D, technologies and talent to create differentiated therapies and platform technologies that address unmet medical needs.
• Integrity - Transparent reporting, compliance with regulatory standards, and ethical conduct in clinical development and commercial activities.
• Collaboration - Strategic alliances with academic institutions, CROs, and commercial partners to de-risk development and accelerate market access.
• Quality assurance - Robust QC/QA systems, traceability, and validation frameworks to ensure product safety, purity and potency.
• Accountability - Clear KPIs, data-driven performance management, and governance that hold teams accountable for outcomes and patient safety.

• Focused R&D allocation - prioritize platform technologies (e.g., monoclonal antibodies, cell therapies) and precision biomarkers to increase probability of clinical success.
• Partnerships & licensing - co-development agreements to share risk, secure market channels and expedite regulatory filings in target regions.
• Manufacturing scale-up - incremental capacity investments and process optimization to reduce COGS and shorten time-to-supply.
• Quality & compliance investments - expand quality control labs, digital batch record systems, and supply-chain audits to meet global standards.
• Commercial readiness - build specialty sales teams, payer engagement strategies, and patient-support programs to maximize access upon approval.

• Board-level oversight of R&D portfolio, risk management and compliance with quarterly reviews.
• KPIs include pipeline progression rates, IND/NDA approval timelines, quality incident rates, time-to-market, and ROI on R&D projects.
• Transparent disclosures on clinical outcomes, safety data, and financial performance to shareholders and regulators.